1. Home
  2. MASK vs CVKD Comparison

MASK vs CVKD Comparison

Compare MASK & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MASK
  • CVKD
  • Stock Information
  • Founded
  • MASK 2017
  • CVKD 2022
  • Country
  • MASK Hong Kong
  • CVKD United States
  • Employees
  • MASK N/A
  • CVKD N/A
  • Industry
  • MASK
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • MASK
  • CVKD Health Care
  • Exchange
  • MASK NYSE
  • CVKD Nasdaq
  • Market Cap
  • MASK 27.7M
  • CVKD 29.5M
  • IPO Year
  • MASK 2025
  • CVKD 2023
  • Fundamental
  • Price
  • MASK $1.29
  • CVKD $11.46
  • Analyst Decision
  • MASK
  • CVKD Strong Buy
  • Analyst Count
  • MASK 0
  • CVKD 1
  • Target Price
  • MASK N/A
  • CVKD $32.00
  • AVG Volume (30 Days)
  • MASK 127.8K
  • CVKD 38.1K
  • Earning Date
  • MASK 01-01-0001
  • CVKD 08-06-2025
  • Dividend Yield
  • MASK N/A
  • CVKD N/A
  • EPS Growth
  • MASK 12.16
  • CVKD N/A
  • EPS
  • MASK 0.19
  • CVKD N/A
  • Revenue
  • MASK $4,718,055.00
  • CVKD N/A
  • Revenue This Year
  • MASK N/A
  • CVKD N/A
  • Revenue Next Year
  • MASK N/A
  • CVKD N/A
  • P/E Ratio
  • MASK $6.52
  • CVKD N/A
  • Revenue Growth
  • MASK 7.89
  • CVKD N/A
  • 52 Week Low
  • MASK $1.12
  • CVKD $5.70
  • 52 Week High
  • MASK $4.19
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • MASK N/A
  • CVKD 42.02
  • Support Level
  • MASK N/A
  • CVKD $10.45
  • Resistance Level
  • MASK N/A
  • CVKD $11.98
  • Average True Range (ATR)
  • MASK 0.00
  • CVKD 0.82
  • MACD
  • MASK 0.00
  • CVKD -0.01
  • Stochastic Oscillator
  • MASK 0.00
  • CVKD 25.19

About MASK 3 E NETWORK TECHNOLOGY GROUP LTD

3 E Network Technology Group Ltd is a business-to-business (B2B) information technology (IT) business solutions provider. It focuses on integrated software and hardware solutions in the property management and exhibition services spaces and expanded software solutions offering to a variety of industries and sectors, including food establishments, real estate, exhibition & conferencing, and clean energy utilities. The business includes two main portfolios, namely the software development portfolio and exhibition and conference portfolio. Maximum revenue is generated from the software development portfolio.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: